Nuformix Regulatory News (NFX)

THIS ANNOUNCEMENT AND THE INFORMATION IN IT, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, NEW ZEALAND, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA")) ("UK MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS WHO RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

11 March 2026

Nuformix plc

("Nuformix" or the "Company" or the "Group")

£1.0 million Placing

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces a placing (the "Placing") to raise gross proceeds of £1.0 million through the issue of 500,000,000 new ordinary shares ("New Ordinary Shares") in the capital of the Company at a price of 0.20 pence per share (the "Issue Price").

The net proceeds of the Placing will be used by the Company to drive forward its NXP002 programme, an inhaled treatment for idiopathic pulmonary fibrosis ("IPF") and progressive pulmonary fibrosis ("PPF") and for general corporate purposes. In particular, the net proceeds will be used to fund a focused programme of additional pre-clinical studies to reinforce areas identified during ongoing out-licensing discussions and due diligence with both large pharmaceutical and speciality pharma partners, and to further advance the NXP002 programme. Whilst completion of the focused studies will represent important value inflection points for the NXP002 programme it is not expected that all the studies will need to conclude for an out-licensing or collaborative development transaction to complete.

CMC Markets UK Plc, trading as CMC CapX ("CMC Markets"), acted as the Company's sole placing agent in respect of the Placing.

Admission and Total Voting Rights

The Placing has been conducted utilising the Directors existing authorities to allot shares. The New Ordinary Shares will rank pari passu in all respects with the existing ordinary shares. The Placing is conditional, inter alia, on there being no breach of the obligations under the Placing Agreement entered into between CMC Markets and the Company prior to Admission, and admission of the New Ordinary Shares to trading on the Main Market of the London Stock Exchange ("Admission") becoming effective.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange and the Equity Shares (Transition) category of the FCA Official List. It is expected that Admission will become effective and that dealings in the New Ordinary Shares on the Main Market of the London Stock Exchange will commence on or around 17 March 2026.

Following Admission of the New Ordinary Shares, the total number of ordinary shares in issue will be 2,609,749,903, each with one voting right. The Company does not hold any rights in treasury. The total voting rights figure is therefore 2,609,749,903 and can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change of their interest in, the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

Enquiries:

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.